Abstract
Purpose: Although post-treatment FDG-PET/CT is frequently obtained following definitive chemoradiation (CRT) for locally advanced anal canal cancer (LAACC), its prognostic utility remains uncertain. We hypothesized that quantitative PET/CT metrics would be associated with overall survival (OS) and that pre-treatment metabolic parameters would provide greater prognostic information than post-treatment metabolic response. Methods: We conducted a retrospective cohort study of patients with LAACC who underwent definitive CRT and both pre-treatment and post-treatment fluorodeoxyglucose (FDG) PET/CT. Quantitative PET metrics were extracted, including mean SUL, total lesion glycolysis (TLG), metabolic tumor volume (MTV), maximum SUL, and peak SUL. OS was estimated using the Kaplan-Meier method. Associations between PET-derived variables and OS were evaluated using univariable Cox proportional hazards regression, with optimal cutoffs identified using maximally selected rank statistics (MaxStat). Results: Forty-five patients were included (median age 57.7 years), with post-treatment PET/CT performed at a median of 4.4 months following CRT. Lean body mass (HR 3.10, 95% CI 1.01–9.50; p = 0.049) and pre-treatment primary tumor mean SUL (HR 4.93, 95% CI 1.40–17.37; p = 0.013), size (HR 4.01, 95% CI 1.22–13.17; p = 0.022), TLG (HR 3.68, 95% CI 1.11–12.14; p = 0.033), and peak SUL (HR 3.31, 95% CI 1.02–10.72; p = 0.046) were associated with OS in exploratory univariable analyses. Post-treatment, higher weight (HR 4.94, 95% CI 1.06–22.96; p=0.041; cutoff 60.42 kg; N=45) and lean body mass (HR 4.82, 95% CI 1.06–21.90; p=0.042; cutoff 44.50 kg; N=44) were associated with worse OS. No post-treatment PET-derived metabolic parameters met the nominal threshold for statistical significance. Among patients with higher baseline metabolic activity, greater reduction in mean SUL following CRT demonstrated a nonsignificant trend toward improved OS. Conclusion: Pre-treatment FDG-PET/CT metabolic parameters demonstrated stronger associations with OS than post-treatment metabolic parameters in this exploratory cohort. Baseline tumor metabolic activity may provide useful prognostic information in patients with LAACC, warranting validation in larger prospective studies.

This publication has 25 references indexed in Scilit: